Potassium levels in women with polycystic ovary syndrome using spironolactone for long-term

IF 3 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Clinical Endocrinology Pub Date : 2023-12-21 DOI:10.1111/cen.15008

Thais A. deOliveira, Lucas B. Marchesan, Poli M. Spritzer

{"title":"Potassium levels in women with polycystic ovary syndrome using spironolactone for long-term","authors":"Thais A. deOliveira, Lucas B. Marchesan, Poli M. Spritzer","doi":"10.1111/cen.15008","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Spironolactone (SPL) has been used to manage hyperandrogenic manifestations in women with polycystic ovary syndrome (PCOS), but data on the risk of hyperkalemia in this population are scarce. The aim of this study was to evaluate the incidence of hyperkalemia in women with PCOS using SPL in the long term.</p>\n </section>\n \n <section>\n \n <h3> Design</h3>\n \n <p>Single-centre retrospective study.</p>\n </section>\n \n <section>\n \n <h3> Patients</h3>\n \n <p>Inclusion and analysis of 98 treatment periods in 78 women with PCOS (20 of whom were duplicates, returning after treatment interruption for a mean of 38 months) who received SPL for a minimum of 12 months and had at least three measurements of potassium levels over time.</p>\n </section>\n \n <section>\n \n <h3> Measurements</h3>\n \n <p>Clinical and hormonal profiles before and during SPL treatment.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Mean age was 29.1 (SD: 9.6) years, and body mass index was 32.2 (SD: 8.1) kg/m². Nine patients had diabetes, and 22 had prediabetes. SPL was used in combination with combined oral contraceptive pills in 55 participants and progestin-only pills/long-acting reversible contraception in 28; metformin was added in 35, and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in 15. Median SPL dose was 100 (range: 50–150) mg. A total of 327 serum potassium measurements were obtained (84 pre-exposure and 243 postexposure). Four potassium measurements were above the reference range before exposure and 19 during exposure. All potassium measurements above the reference range during follow-up were classified as mild hyperkalemia (5.1–5.5 mEq/L).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The present findings suggest that women with PCOS, without kidney or heart disease, using SPL combined with hormonal contraception for managing clinical hyperandrogenism have a low incidence of hyperkalemia and well-tolerated minor adverse effects.</p>\n </section>\n </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen.15008","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Spironolactone (SPL) has been used to manage hyperandrogenic manifestations in women with polycystic ovary syndrome (PCOS), but data on the risk of hyperkalemia in this population are scarce. The aim of this study was to evaluate the incidence of hyperkalemia in women with PCOS using SPL in the long term.

Design

Single-centre retrospective study.

Patients

Inclusion and analysis of 98 treatment periods in 78 women with PCOS (20 of whom were duplicates, returning after treatment interruption for a mean of 38 months) who received SPL for a minimum of 12 months and had at least three measurements of potassium levels over time.

Measurements

Clinical and hormonal profiles before and during SPL treatment.

Results

Mean age was 29.1 (SD: 9.6) years, and body mass index was 32.2 (SD: 8.1) kg/m². Nine patients had diabetes, and 22 had prediabetes. SPL was used in combination with combined oral contraceptive pills in 55 participants and progestin-only pills/long-acting reversible contraception in 28; metformin was added in 35, and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in 15. Median SPL dose was 100 (range: 50–150) mg. A total of 327 serum potassium measurements were obtained (84 pre-exposure and 243 postexposure). Four potassium measurements were above the reference range before exposure and 19 during exposure. All potassium measurements above the reference range during follow-up were classified as mild hyperkalemia (5.1–5.5 mEq/L).

Conclusions

The present findings suggest that women with PCOS, without kidney or heart disease, using SPL combined with hormonal contraception for managing clinical hyperandrogenism have a low incidence of hyperkalemia and well-tolerated minor adverse effects.

查看原文本刊更多论文

长期使用螺内酯的多囊卵巢综合征妇女的血钾水平。

目的：螺内酯（SPL）已被用于控制多囊卵巢综合征（PCOS）女性患者的高雄激素表现，但有关该人群高钾血症风险的数据却很少。本研究旨在评估长期使用 SPL 的多囊卵巢综合征女性患者的高钾血症发生率：设计：单中心回顾性研究：纳入并分析了78名多囊卵巢综合征女性患者的98个治疗期（其中20名患者为重复患者，在中断治疗平均38个月后重新接受治疗），这些患者至少接受了12个月的SPL治疗，并在此期间至少测量了三次血钾水平：测量： SPL 治疗前和治疗期间的临床和激素概况：平均年龄为 29.1 岁（标准差：9.6 岁），体重指数为 32.2 公斤/平方米（标准差：8.1 公斤/平方米）。9名患者患有糖尿病，22名患者患有糖尿病前期。55名患者在使用SPL的同时服用了复方口服避孕药，28名患者服用了纯孕激素避孕药/长效可逆避孕药；35名患者服用了二甲双胍，15名患者服用了血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂。SPL 的中位剂量为 100 毫克（范围：50-150 毫克）。共进行了 327 次血清钾测量（暴露前 84 次，暴露后 243 次）。暴露前有 4 次血钾测量值高于参考值范围，暴露期间有 19 次。随访期间所有高于参考范围的钾测量值均被归类为轻度高钾血症（5.1-5.5 mEq/L）：本研究结果表明，患有多囊卵巢综合症且无肾脏或心脏疾病的妇女在使用 SPL 联合激素避孕法治疗临床高雄激素症时，高钾血症的发生率较低，且不良反应轻微，可以很好地耐受。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Endocrinology 医学-内分泌学与代谢

CiteScore

6.40

自引率

3.10%

发文量

192

审稿时长

1 months

期刊介绍： Clinical Endocrinology publishes papers and reviews which focus on the clinical aspects of endocrinology, including the clinical application of molecular endocrinology. It does not publish papers relating directly to diabetes care and clinical management. It features reviews, original papers, commentaries, correspondence and Clinical Questions. Clinical Endocrinology is essential reading not only for those engaged in endocrinological research but also for those involved primarily in clinical practice.